Article Information
History
- February 23, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Uriel Trahtemberg, MD, PhD1,
- Robert Rottapel, MD2,3,
- Claudia C dos Santos, MD1,4,5,
- Arthur S. Slutsky, MD4,5,
- Andrew J Baker, MD1,4,5 and
- Marvin J Fritzler, MD, PhD*,6
- on behalf of the COVID19 Longitudinal Biomarkers of Lung Injury (COLOBILI) group.
- 1Critical Care Department, St. Michael’s Hospital, Toronto, ON, Canada
- 2Departments of Medicine and Immunology, University of Toronto, Toronto, ON, Canada
- 3Division of Rheumatology, St. Michael’s Hospital, Toronto, ON, Canada
- 4Keenan Centre for Biomedical Research, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, ON, Canada
- 5Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada
- 6Cumming School of Medicine, University of Calgary, Calgary, AB Canada
- ↵*Corresponding author: Marvin J. Fritzler PhD MD, Cumming School of Medicine, University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, Canada T2N 4N1, Email: fritzler{at}ucalgary.ca, Telephone: +01-403-220-3533
Posted February 23, 2021.
Anti-cardiolipin and other anti-phospholipid antibodies in critically ill COVID-19 positive and negative patients
